U.S. Surgical to Acquire Confluent Surgical

In a move to compete more effectively in the growing biosurgery market, U.S. Surgical (Norwalk, CT, USA) has entered into a definitive agreement to acquire Confluent Surgical (Waltham, MA, USA) for U.S.$245 million. U.S. Surgical is a subsidiary of Tyco Healthcare (Pembroke, Bermuda).

Confluent Surgical is a privately held company developing polymer-based technology of in-situ polymerized hydrogels and associated delivery systems used in sprayable surgical sealants and anti-adhesion products. The company markets a neurosurgical sealant called DuraSeal that was the first product to receive U.S. Food & Drug Administration (FDA) approval for use in cranial dural repair. This sealant, along with several other products in the company's pipeline, is intended to improve patient outcomes by reducing leaks or adhesions across various surgical specialties. The biosurgery market is currently estimated at $900 million and is expected to double in size within the next six years.

"Confluent Surgical is an excellent strategic fit for Tyco Healthcare. This acquisition will expand U.S. Surgical's Syneture suture product portfolio, as well as the Autosuture division's surgical stapler franchise,” said Rich Meelia, CEO of Tyco Healthcare. "Confluent's products and technology will be a welcomed addition to Tyco Healthcare's extensive surgical portfolio.”



Related Links:
Confluent Surgical
U.S. Surgical